OPK · Opko Health, Inc.
Market Cap
$1.10B
Shares
746.33M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jon R. Cohen | Senior Vice President-OPKO | $3,434,600 |
| Adam Logal | Senior Vice President and Chief Financial Officer | $1,902,100 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jon R. Cohen | Senior Vice President-OPKO | $3,491,200 |
| Adam Logal | Senior Vice President and Chief Financial Officer | $1,552,200 |
| Phillip Frost | Chief Executive Officer | $1,538,200 |
| Jane H. Hsiao | Chief Technical Officer | $1,478,200 |
| Steven D. Rubin | Executive Vice President- Administration | $1,262,200 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| OPKO Health | Inc.; Executive Chairman-BioReference Health, LLC | $2,297,200 |
| Jon R. Cohen | Senior Vice President-OPKO | $2,297,200 |
| Phillip Frost | Chief Executive Officer | $1,405,200 |
| Jane H. Hsiao | Chief Technical Officer | $1,345,200 |
| Steven D. Rubin | Executive Vice President- Administration | $1,131,200 |
| Adam Logal | Senior Vice President and Chief Financial Officer | $921,200 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Phillip Frost | Chief Executive Officer | $2,036,000 |
| Jane H. Hsiao | Chief Technical Officer | $1,976,000 |
| Steven D. Rubin | Executive Vice President- Administration | $1,460,000 |
| Adam Logal | Senior Vice President and Chief Financial Officer | $1,250,000 |
| OPKO Health | Inc.; Executive Chairman-BioReference Laboratories, Inc. | — |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Phillip Frost | Chief Executive Officer | $970,800 |
| Jane H. Hsiao | Chief Technical Officer Steven D. Rubin^^ | $915,800 |
| Adam Logal | Senior Vice President and Chief Financial Officer | $610,800 |
Key facts
CIK
944809
CUSIP
68375N103
13F (30d)
170 filings
169 filers
Visit website
Investor relations